Format

Send to

Choose Destination
Value Health. 2014 Dec;17(8):888-94. doi: 10.1016/j.jval.2014.08.2673. Epub 2014 Nov 4.

Evolution of drug reimbursement in Canada: the Pan-Canadian Pharmaceutical Alliance for new drugs.

Author information

1
Institute of Health Economics, Edmonton, AB, Canada; Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada. Electronic address: dhusereau@ihe.ca.
2
3Sixty Public Affairs, Inc., Ottawa, ON, Canada.
3
Norton Rose Fulbright Canada, Montreal, QC, Canada.

Abstract

Canada has a unique system of public drug coverage and reimbursement characterized by a centralized review agency that makes funding recommendations along with decentralized authority for delivering health care across 10 provinces and three territories. There has been a significant increase in price negotiation for new pharmaceuticals in the past 10 years, first by individual provinces and now through a collective price negotiation process called the "Pan-Canadian Pharmaceutical Alliance." As of February 2014, the Pan-Canadian Pharmaceutical Alliance has already completed 32 negotiations despite still being in a formative stage; it is anticipated that a formal process will be developed in the coming year. In this article, we describe the evolution of price negotiation in Canada and identify several opportunities for improvement of the current process, including the incorporation of economic considerations into price negotiation.

KEYWORDS:

advisory committees/organization & administration Canada; decision making; legislation and jurisprudence; pharmaceutical reimbursement

PMID:
25498784
DOI:
10.1016/j.jval.2014.08.2673
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center